Immune Responses To Antigen-Bearing Dendritic Cells in Patients With Malignancy

PHASE1CompletedINTERVENTIONAL
Enrollment

43

Participants

Timeline

Start Date

September 30, 2001

Primary Completion Date

April 30, 2011

Study Completion Date

April 30, 2011

Conditions
Melanoma
Interventions
BIOLOGICAL

dendritic cell vaccine

"The vaccine will be split between as many as 10 injections, more or less. Each shot will be about 1/25th to 1/50th of a teaspoon (100 to 200 microliters). Each vaccine will be injected with a tiny needle just under your skin. This will usually cause a very small area of swelling at the injection site that may last for a few minutes to an hour or so. You will receive two additional booster doses of the same vaccine every 4-6 weeks. This would mean that you receive a total of three vaccines over about 2-3 months."

Trial Locations (1)

10065

Memorial Sloan Kettering Cancer Center, New York

All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

collaborator

National Institutes of Health (NIH)

NIH

collaborator

Rockefeller University

OTHER

lead

Memorial Sloan Kettering Cancer Center

OTHER

NCT00700167 - Immune Responses To Antigen-Bearing Dendritic Cells in Patients With Malignancy | Biotech Hunter | Biotech Hunter